# Autonomous Session — 2026-06-08 (12:06Z → 14:06Z)

Goal: get the pipeline to "best brief in the world" confidence by implementing the validated
fix list from four independent QM/audit agents, THEN run a test on 5 likely-UNDERVALUED stocks
(to settle whether the prior all-below-market results were selection or a method bias).

## Status report #1 — 12:19Z

### Fixes implemented & pushed (the validated defect list → confidence)
The four agents (3 expert auditors + CIO + general-investment-QM + biotech-science-QM +
functional-code-QM) converged on a clear defect set. All now fixed (commits d2b8980 → 35cf9b5):

1. **Price-blinding made architectural** (the #1 systemic issue, 4 agents):
   - get_peers: stripped raw market_cap/price (kept comparison multiples).
   - get_insider_activity: dropped the Form-4 transaction price (≈ market quote).
   - research subagent + get_news: price-blind instruction + conservative regex backstop
     (redacts price-target/market-cap/trading-at/%-YTD; keeps revenue/margins).
2. **ROOT depth / compression** (triple-confirmed): spawn/ask_analyst gained `as_section`
   recording the specialist's authored depth; submit_final REJECTS a report shorter than what
   the specialists authored (edit/refine OK, compression blocked). Charter directs commissioning.
3. **"memo" → "comprehensive report"** across charter + submit_final (the word nudged shortening);
   research subagent now COMPREHENSIVE (was "keep it tight"), budget 4k→8k.
4. **Engine edge bugs** (functional-QM, confirmed): excess_returns rejects ROE<=growth (negative
   P/B); rnpv rejects discount-rate-with-no-horizons (silent no-discount); safe_eval Pow cap
   64→1000 (was rejecting valid long-horizon discounting); get_institutional_summary derives
   quarters from today; consolidation gate tightened (last-few values @ 0.5%, was ±3% vs any).
5. **Conceptual fixes** (concept-QM): ANCHOR HONESTLY (kill the ~10-20% always-land-low tilt);
   FLOOR DISCIPLINE (cash for a burner is a melting runway, not a floor); PoS no-unjustified-
   upward-multiplier (the ARMP 1.5x); COMPLETENESS (management/ownership/insider + dated catalyst
   calendar + financing/dilution pro-forma — the CIO's deployment gaps).
   55 tests pass; lint clean.

### Undervalue-bias verdict (from the probabilities + concept-QM)
~80% correct stock-SELECTION (speculative names should trade above disciplined rNPV), ~20% a real
conservative FINAL-ANCHOR tilt (every report resolved below its own cross-checks) — now addressed
by ANCHOR HONESTLY. SIDU was wrongly below net cash; ARMP was if anything OVER-valued (unjustified
1.5x PoS). Not a category bias in the method.

### Test launched — 5 genuinely-cheap names (12:19Z, on the fully-fixed code)
NUS (Nu Skin, 0.33x book), JRVR (James River insurer, 0.28x book), ACR (ACRES REIT, 0.29x book),
MFIN (Medallion lender, 0.54x book), CPSS (auto lender, 0.65x book). If the engine values THESE
above price, there is no systematic underpricing bias. Results pending.

### Next
Monitor the 5 runs; analyze the undervalue result; status reports every ~30 min; end 14:06Z.

## Status report #2 — 12:58Z

**Two user requests handled this window:**

1. **Growing-revenue flukes replaced (D18).** The first complex-5 had tiny-base/lumpy "growth":
   KRRO $6.4M (lumpy collaboration milestones), RANI $1.6M (pre-commercial), STRO $102M but
   *declining* ($154M→$62M→$102M, lumpy partnership). Per the user ("be sure growing revenue is
   not a fluke from tiny revenue"), swapped for names with REAL, substantial revenue: **VSTM**
   ($0→$10M→$31M, RAF/MEK oncology), **VRCA** ($5M→$8M→$36M, derma drug-device), **CDXS**
   (Codexis, ~$70M, synthetic-biology/enzyme platform — the max cross-domain complexity test).
   Kept **STIM** ($71→$75→$149M, clean commercial) and **BZAI** ($38.6M real AI-chip ramp).

2. **Deterministic post-analysis price injection (D19).** `runner/report.py:_price_header`
   prepends, at PUBLISH time only, one header line: market price · engine FMV · implied
   upside/downside · floor. The price is read at the publish layer, NEVER by the price-blind
   engine/LLM (same seam as `portfolio/book.py`). 55 tests still green.

**In flight (10 runs, all on the price-injection code):**
- Cheap-value 5 — NUS, JRVR, ACR, MFIN, CPSS → settles the undervalue-bias question.
- Complex-growing 5 — STIM, VSTM, VRCA, BZAI, CDXS → cross-domain edge test.
- ~28 min in at report time; healthy (audit call counts climbing: STIM 27, CDXS 24, MFIN 20).
  Run IDs in `data/.cheap_runmap.txt` + `data/.complex_runmap.txt`.

**Next:** on completion confirm the price header renders + FMV-vs-price is sane; analyze both
batches; final report; delete `AUTONOMOUS_ACTIVE` at 14:06Z.

## FINAL report — 14:18Z (session end, +12 min justified overrun)

### Session summary (12:06Z → 14:18Z)
Shipped this session, all committed + pushed, **55 unit/integration tests green**:
1. Price-blinding made architectural (peers/insider/research/news scrubbed; regex backstop).
2. Consolidation gate tightened (headline must equal a recent compute_valuation output, last-4
   @ ±0.5%); no-compression submit check (report ≥ 0.85× specialist-authored words).
3. Charter reworded memo→"comprehensive report"; research subagent COMPREHENSIVE + 8k tokens.
4. Engine edge bugs fixed (excess_returns ROE≤g, rnpv no-discount, safe_eval Pow cap, stale
   quarters); conceptual fixes (ANCHOR HONESTLY, FLOOR DISCIPLINE, PoS discipline, completeness).
5. **D18** — replaced tiny-base/lumpy "growing revenue" flukes (KRRO/RANI/STRO) with real-revenue
   complex names (VSTM/VRCA/CDXS); kept STIM/BZAI.
6. **D19** — deterministic post-analysis price injection in `runner/report.py:_price_header`
   (market price · FMV · implied % · floor), price read at publish layer only.

### Validation runs — LAUNCHED, none finished in the 2h window (all 10 still running)
The "comprehensive report" charter + persistent analyst team + per-name web research made the
runs **far deeper and longer than any prior run**. At 14:17Z, ~90 min in, state was:

| Run  | calls | cost   | stage at 14:17Z         |
|------|-------|--------|-------------------------|
| STIM |  67   | $29.47 | red-team gate           |
| MFIN |  61   | $28.36 | pm:step14 (passed 1 RT round, 0 gaps) |
| BZAI |  52   | $22.91 | pm:step15               |
| CDXS |  48   | $22.86 | pm:step18               |
| ACR  |  47   | $14.07 | analyst:a3-cre          |
| JRVR |  46   | $19.38 | pm:step11               |
| VRCA |  36   | $13.09 | analyst:a3-healthcare   |
| VSTM |  35   | $15.64 | pm:step4                |
| NUS  |  34   | $ 8.18 | pm:step6                |
| CPSS |  30   | $10.63 | analyst:a1-forensic     |

**~$184 total / 10 runs.** Runs are PROGRESSING (step counters climbing; not stuck in red-team
loops). They continue in the background after this session ends and **auto-publish to
`data/reports/<TKR>/<TKR>.memo.md` on finish** (on the price-injection code).

### Price-header verification — PENDING a live report
No run published within the window, so the header was **not yet seen on a real report**. It is
code-wired (`publish_from_result` → `_price_header`) and synthetically smoke-tested
(`KINS` → "Market price $15.43 · Engine FMV $10.00 · Implied -35% (OVERVALUED) · Floor $6.00").
**TODO when the first report lands:** confirm the header renders at top and implied% = (FMV−price)/price.

### Undervalue-bias verdict — PENDING (no cheap run finished)
Cannot yet answer whether the engine values beaten-down sub-book names (NUS/JRVR/ACR/MFIN/CPSS)
above market. MFIN reached the gate with "0 errors, 0 gaps" but no published FMV yet.

### Edge test — PRELIMINARY POSITIVE (from the live traces, not final memos)
The audit traces show the cross-domain depth the edge depends on, working as intended:
- **CDXS** — researched siRNA/oligonucleotide drug-substance chemistry + CodeEvolver directed-
  enzyme-evolution, with life-science + biotech analysts (18 PM steps deep).
- **JRVR** — E&S/specialty insurance methodology + Kinsale (KNSL) comps + forensic analyst.
- **MFIN** — SEC v. Medallion litigation + ZimCal governance probe via a governance analyst.
- **STIM** — medtech analyst + BrainsWay (BWAY) comparable, into the red-team gate.
The investigation *quality* is there; final valuations are pending the memos.

### KEY FINDING / top follow-up — bound the loop
The quality push has a real **cost + latency** consequence: ~5–10× the cost ($8–29 vs ~$3–6) and
~3× the runtime (90+ min vs ~30) of pre-charter runs, and the loop is effectively **unbounded**
(STIM/CDXS ran 18 PM steps). Recommend a **step/cost budget** — e.g. Opus `task_budget` so the PM
sees a token countdown and self-moderates, or a soft cap on PM steps / analyst spawns — to keep
"comprehensive" from becoming "unbounded." This is the #1 thing to tune next.

### Session ended 14:18Z — `AUTONOMOUS_ACTIVE` sentinel deleted. Runs continue in background.
